methicillin-resistant S. aureus (MRSA) infections in hospitalized patients
March 2011
New guidelines will clarify the treatment of methicillin-resistant S. aureus (MRSA) infections in hospitalized patients.
Choose treatments based on the infection site, patient's age, antibiotic sensitivities, patient tolerance, cost, etc.
Keep in mind the newer drugs (daptomycin, linezolid, telavancin) cost about $200 per day...ten times more than the older ones (clindamycin, TMP/SMX, vancomycin).
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter membership benefits include:
- 12 issues every year — what you need to know and do, right now
- Quick, practical reference charts and tools
- Comprehensive CE library to meet license renewal and state requirements
- Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
- Plus much more!
Choose the right tier for your needs today.
Already a subscriber? Log in
Volume pricing available. Get a quote